Decreased serum fetuin-A levels and active inflammatory bowel disease

American Journal of the Medical Sciences

Volumn 348, Issue 1, 2014, Pages 47-51

  Ma, Peng ^a,b   Feng, Yi Chao ^a  

^a YAN'AN UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarker; Crohn's disease; Fetuin A; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; C REACTIVE PROTEIN; FETUIN A; IMMUNOSUPPRESSIVE AGENT; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; REMISSION; ULCERATIVE COLITIS;

ADULT; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED;

EID: 84903266576     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000195     Document Type: Article

References (27)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448: 427-34.
2. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in II10-/- mice. Nature 2012;487: 104-8.
3. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis 2010;11: 76-82.
4. Manolakis AC, Kapsoritakis AN, Georgoulias P, et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 2010;10:118.
5. Wang H, Sama AE. Anti-inflammatory role of fetuin-a in injury and infection. Curr Mol Med 2012;12: 625-33.
6. Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945.
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24(Suppl): 2-6.
8. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70: 439-44.
9. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106: 287-96.
10. Gejyo F, Schmid K. Purification and characterization of the two forms of human plasma alpha 2HS-glycoprotein. Biochim Biophys Acta 1981; 671: 78-84.
11. Chen HY, Chiu YL, Hsu SP, et al. Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. Eur J Endocrinol 2009;160: 777-83.
12. Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. Adv Clin Chem 2012;56: 175-95.
13. Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum 2009;60: 2037-45.
14. Kalabay L, Cseh K, Jakab L, et al. Diagnostic value of the determination of serum alpha2-HS-glycoprotein. Orv Hetil 1992;133:1553-4; 1559-60.
15. Weeke B, Jarnum S. Serum concentration of 19 serum proteins in Crohn's disease and ulcerative colitis. Gut 1971;12: 297-302.
16. Bergin DA, Greene CM, Sterchi EE, et al. Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem 2008;283: 31736-44.
17. Banerjee S, Bond JS. Prointerleukin-18 is activated by meprin beta in vitro and in vivo in intestinal inflammation. J Biol Chem 2008;283: 31371-77.
18. Herzog C, Haun RS, Kaushal V, et al. Meprin A and meprin alpha generate biologically functional IL-1beta from pro-IL-1beta. Biochem Biophys Res Commun 2009;379: 904-8.
19. Hedrich J, Lottaz D, Meyer K, et al. Fetuin-A and cystatin C are endogenous inhibitors of human meprin metalloproteases. Biochemistry 2010;49: 8599-607.
20. Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol 2011;106: 2029-40.
21. McDonnell M, Liang Y, Noronha A, et al. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis 2011;17: 298-307.
22. Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945.
23. Laughlin GA, Cummins KM, Wassel CL, et al. The association of fetuin-A with cardiovascular disease mortality in older communitydwelling adults: the Rancho Bernardo study. J Am Coll Cardiol 2012; 59: 1688-96.
24. Vörös K, Gráf L Jr, Prohászka Z, et al. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 2011;41: 703-9.
25. Michigan A, Johnson TV, Master VA. Review of the relationship between C-reactive protein and exercise. Mol Diagn Ther 2011;15: 265-75.
26. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10: 661-5.
27. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55: 426-31.